Enhanced probiotic viability in low-ph beverages via non-aqueous encapsulation
DermBiont's proprietary non-aqueous matrix encapsulation enhances probiotic viability in acidic beverages without refrigeration, offering a novel solution for functional foods.
Overview
DermBiont has developed an innovative encapsulation technique that significantly enhances the viability and stability of probiotics in low-pH beverages. Utilizing a proprietary non-aqueous matrix, this solution ensures probiotics maintain their potency and stability for up to two years without the need for refrigeration. This breakthrough addresses the challenge of incorporating live probiotics into acidic beverages, providing a new avenue for the development of functional foods.
Technical specifications
The technology leverages a food-grade, GRAS-certified non-aqueous matrix that preserves probiotic viability in harsh conditions. Key features include:
- Utilization of hydrophobic materials for moisture protection
- Compatibility with food processing, packaging, and gastrointestinal transit
- Proven stability in low-pH environments for up to two years
The encapsulation process involves suspending live probiotics in a non-aqueous matrix, forming an emulsion that is compatible with beverage matrices while ensuring consumer safety.
Technology readiness level
Currently at TRL 3, this technology has demonstrated proof of concept in laboratory settings. Future validation will focus on optimizing the encapsulation process, stability testing in simulated environments, sensory impact evaluations, and in vivo trials to confirm probiotic survival and health efficacy. Partnerships with food scientists and regulatory experts will facilitate compliance and scalability for commercial implementation.
About DermBiont
DermBiont is a biotechnology company focused on developing precision dermatology treatments that address the root causes of skin diseases. The company utilizes a dual-platform approach to therapeutic development: a computational biology platform that analyzes skin microbiome data to create biotherapeutics, and a discovery platform dedicated to targeted small molecule therapeutics. By focusing on these well-defined mechanisms of action, the company aims to move beyond merely treating symptoms and instead provide effective cures for various dermatological conditions. Their lead candidate, SM-030, is a first-in-class topical PKC-beta inhibitor currently being advanced for the treatment of melasma and other hyperpigmentation disorders.
This research is significant for patients suffering from persistent skin conditions, as the company works to fill unmet needs through clinical programs that prioritize efficiency in both timelines and budget. DermBiont’s broader pipeline includes candidates for indications such as seborrheic keratosis, atopic dermatitis, and fungal infections like tinea pedis and onychomycosis. By combining expertise in small molecule development with innovative microbiome insights, DermBiont aims to become a leader in the commercialization of targeted topical therapeutics that improve skin health and quality of life for millions.
delivered to your inbox.